WS05: How to ensure robustness and reproducibility when using mass cytometry for clinical trials
Escobar, D.L.B., Estevam, J., Leipold, M., et al.
Mass cytometry is a cutting‐edge technology that merges the high‐throughput single cell analysis with the specificity and resolution of mass spectrometry. It allows over forty parameters to be measured simultaneously on single cells, allowing deeper profiling of samples. While mass cytometry has highly contributed to basic scientific discovery, some of the major challenges come when trying to implement this technology in clinical studies. The addition of mass cytometry to the pool of technologies in clinical studies requires better standardization and quality control. Discussion on the validation of mass cytometry assays for clinical use including application validation, reagents and protocols, instrument operation, quality control, and data analysis is needed. We gathered experts in the field to learn from their experience on how to overcome these challenges. The intent of the workshop was to address the challenges in implementing mass cytometry in clinical studies and discuss solutions adapted by experts in the field. By the conclusion of the workshop, the audience had a better understanding of the key points that require optimization to ensure high quality, reproducible data. Consensus was provided by the expert panel for successful implementation of mass cytometry in clinical studies.
Escobar, D.L.B., Estevam, J., Leipold, M., et al. "WS05: How to ensure robustness and reproducibility when using mass cytometry for clinical trials" Cyt-Geist: Current and Future Challenges in Cytometry: Reports of the CYTO 2019 Conference Workshops (2019): 1,264-1,268